Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
NCT01464411 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2011-11-03
Summary
The purpose of this study is to evaluate effectiveness of Dasatinib as the first line therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase in Japan.
Conditions
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Myelogenous Leukemia, Chronic, Chronic Phase
Sponsors & Collaborators
-
Kanto CML Study Group
lead OTHER
Eligibility
- Min Age
- 20 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-07-31
Countries
- Japan
Study Locations
More Related Trials
-
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
NCT04925141 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
NCT00482703 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
NCT03216070 ·Status: UNKNOWN ·Phase: PHASE4
-
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL
NCT01004497 ·Status: COMPLETED ·Phase: PHASE2
-
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
NCT02348957 ·Status: COMPLETED
-
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
NCT00777036 ·Status: COMPLETED ·Phase: PHASE2
-
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
NCT03625388 ·Status: COMPLETED ·Phase: PHASE2
-
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
NCT01627132 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
NCT00130195 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT03671564 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
NCT00324194 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
NCT00324129 ·Status: COMPLETED ·Phase: PHASE1
-
Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
NCT00345826 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
NCT04241549 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00923182 ·Status: COMPLETED ·Phase: PHASE1
-
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
NCT02709083 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years
NCT00219752 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
NCT00320190 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
NCT00362466 ·Status: TERMINATED ·Phase: PHASE3
-
Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients
NCT04150471 ·Status: UNKNOWN
-
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
NCT00254423 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia
NCT00852566 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia
NCT02113319 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
NCT01043874 ·Status: COMPLETED ·Phase: PHASE4
-
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT00070499 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2